RNAZ TransCode Therapeutics, Inc.: Net earnings per one share for the last twelve months
TransCode Therapeutics (RNAZ) utilizes the innovative TTX system for the targeted destruction of metastases. The 12-month annual growth in earnings per share illustrates the financial dynamics, where the current level is 86.80. However, a liquidity deficit and shareholder dilution, combined with the risks of disrupted logistics chains from Asia, are exerting significant pressure on the company's capitalization.
%20transcodetherapeutics.com%20%5Blogo%5D%20RNAZ&width=1200&height=400&colorIndex=0&v=mwa76aez.ocr-7cpmfb4&start=20220704&end=20261110&filename=GURU_Markets_-_RNAZ_-_TransCode-Therapeutics_-_Net-earnings-per-share-EPS-TTM "RNAZ (TransCode) Earnings per share for the last 12 months history from 02/11/2024 to 11/10/2026 | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for TransCode (RNAZ)
- market value and analyst target forecast:
- company stock capitalization data:
- company book value details:
- company total debt and liquidity indicators:
All Debt to Shareholders' Equity Ratio TransCode Therapeutics|RNAZ - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio TransCode Therapeutics|RNAZ - Company Aggregate Debts|Debt to Net Assets Ratio TransCode Therapeutics Inc.|RNAZ - Company Long-Term Debts|Short-Term Debt TransCode Therapeutics|Intermediate Coverage Ratio transcodetherapeutics.com
- earnings and valuation multiples information:
RNAZ - Net Profit|Projected Future Earnings TransCode Therapeutics|RNAZ - Price to Earnings Ratio|Price to Expected Earnings Ratio TransCode Therapeutics|RNAZ - PEG Multiple|Company Value to EBITDA TransCode Therapeutics Inc.|RNAZ - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) TransCode Therapeutics|RNAZ - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months transcodetherapeutics.com|RNAZ - Earnings growth in current year|Consensus forecast of earnings per share growth for next year TransCode Therapeutics
Fundamental company valuation:TransCode Therapeutics, Inc. RNAZ
The operational dynamics of TransCode Therapeutics (RNAZ) are reflected in the rolling year-over-year (YoY) change in earnings per share. This metric captures the annual growth of net income attributable to a single common share, with calculations based on a comparison of the current TTM value against the same period last year. Within the biotechnology sector, this trend is secondary to the clinical success of RNA therapy. Investors utilize this chart to monitor financial stability during capital raising periods.
Competitor analysis for TransCode Therapeutics
Tempus AI, Inc. (TEM) - Net earnings per share for the last 12 months|Qiagen (QGEN) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Ionis Pharmaceuticals, Inc. (IONS)|RGEN (Repligen Corp.) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months RNA (Avidity Corp)|Net earnings per share (EPS TTM) CRSP|WGS - Net earnings per one share for the last twelve months|Ultragenyx - Net earnings per share for the last 12 months|Earnings per share for the trailing year BEAM|SRPT: Net earnings per share for the last 12 months|Twist Bioscience Corp - Earnings per share for the last four quarters|TXG: Net earnings per share (EPS TTM)|intelliatx.com - Earnings per share for the trailing year|STOK (Stoke Therapeutics, Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months BioLife Solutions Inc BLFS|Earnings per share for the last twelve months Wave Life Sciences Corp (WVE)|MAZE (Maze Therapeutics Corp) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) SION (Sionna Therapeutics Inc)|Net earnings per share (EPS TTM) primemedicine.com PRME|TSHA - Earnings per share for the last twelve months|Earnings per one share for the last 12 months QURE|MGTX: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months REGENXBIO Corp (RGNX)|Net earnings per share for the last 12 months SLDB|Net earnings per share (EPS TTM) ocugen.com|Net earnings per share for the last 12 months PACB (PacBio)|Earnings per share for the last four quarters BNTC|Net earnings per share (EPS TTM) DSGN (Design Pharma)|Net earnings per share for the last four quarters Rocket Corp (RCKT)|4D Molecular Therapeutics - Net earnings per share (EPS TTM)|Lexeo Therapeutics (LXEO) - Net earnings per share for the last 12 months|korrobio.com (KRRO) - Earnings per share for the last twelve months|EDIT - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Silence Therapeutics Inc.|PRQR: Earnings per share for the trailing year|Earnings per share for the last twelve months Codexis, Inc. (CDXS)|sangamo.com - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) NAUT (Nautilus Bio)|Net earnings per share (EPS TTM) Metagenomi Inc. MGX|DTIL: Net earnings per share for the last 12 months|Earnings per one share for the last 12 months GBIO|BOLD: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months XCUR|Earnings per share for the last twelve months Imunon Inc|Earnings per share for the last 12 months PHIO (RXi Pharmaceuticals)|Net earnings per share (EPS TTM) MBIO|Net earnings per share (EPS TTM) bionanogenomics.com (BNGO)|Applied DNA Sciences - Net earnings per share for the last 12 months|Earnings per share for the last four quarters BLUE (bluebirdbio.com)|IPA - Earnings per share for the last twelve months|Earnings per share for the trailing year OMGA (Omega Therapeutics Inc)|OMIC: Net earnings per share (EPS TTM)|Regulus (RGLS) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Syros Pharmaceuticals|Earnings per share for the last 12 months TBIO (telesisbio.com)|Earnings per share for the last twelve months TRACON Pharmaceuticals, Inc. (TCON)|Net earnings per share for the last four quarters Unity Biotechnology Inc.
